Similarly, the SURMOUNT trials evaluating tirzepatide for weight management did not report increased rates of panic symptoms compared to placebo, though it's important to note that panic symptoms were not prespecified outcomes in these studies
Clinical outcomes The primary end points were the participant incidence of TEAEs, changes in laboratory safety tests, vital signs and 12-lead electrocardiograms
Ghrelin and ghrelin receptor agonists stimulate gastrointestinal motility through vagal afferent pathways and direct effects on enteric neurons
Basic science and careful clinical trials gave us what appears to be, for many, a wonder drug
Reducing the risk of major cardiovascular events like heart attack, stroke, or death in adults with type 2 diabetes and known heart disease
It is crucial to emphasise that these mechanisms remain largely theoretical regarding tirzepatide specifically